Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Acromegaly - Overview
Acromegaly - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Acromegaly - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Acromegaly - Companies Involved in Therapeutics Development
Antisense Therapeutics Ltd
Aquestive Therapeutics Inc
Ascil Proyectos SL
Auritec Pharmaceuticals Inc
Camurus AB
Chiasma Inc
Crinetics Pharmaceuticals Inc
Daewoong Pharmaceutical Co Ltd
Dauntless Pharmaceuticals Inc
DexTech Medical AB
Enesi Pharma Ltd
Foresee Pharmaceuticals Co Ltd
GeneScience Pharmaceuticals Co Ltd
GlyTech Inc
Ionis Pharmaceuticals Inc
Italfarmaco SpA
OPKO Health Inc
Pharmathen Global BV
Strongbridge Biopharma plc
Acromegaly - Drug Profiles
atesidorsen sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DP-2018 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FP-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IONIS-GHRLRx - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ITF-2984 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lanreotide SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MOD-12014 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
octreotide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
octreotide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
octreotide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
octreotide acetate CR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
octreotide acetate DR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
octreotide acetate microspheres - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
octreotide LA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
octreotide LA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
octreotide SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
paltusotine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Somadex - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Agonize Somatostatin Receptors for Acromegaly - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
veldoreotide ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
veldoreotide IR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Acromegaly - Dormant Projects
Acromegaly - Discontinued Products
Acromegaly - Product Development Milestones
Featured News & Press Releases
Sep 04, 2020: Crinetics Pharmaceuticals provides new data from Paltusotine and ACTH antagonist development programs at European Congress of Endocrinology
Aug 31, 2020: Chiasma announces U.S. commercial launch and availability of MYCAPSSA, the first and only oral somatostatin alog for patients with acromegaly
Aug 17, 2020: Chiasma announces publication of pivotal data from the phase 3 CHIASMA OPTIMAL clinical trial in the jourl of Clinical Endocrinology & Metabolism
Jul 27, 2020: Chiasma announces 48-week safety and efficacy data from the open-label extension study of its CHIASMA OPTIMAL phase 3 trial evaluating MYCAPSSA in patients with acromegaly
Jul 08, 2020: Crinetics Pharmaceuticals receives orphan drug desigtion for Paltusotine for the treatment of acromegaly
Jul 02, 2020: Camargo client Chiasma receives FDA approval for first and only oral somatostatin alog for long-term maintence treatment of acromegaly
Jun 26, 2020: Chiasma announces FDA approval of MYCAPSSA (Octreotide) capsules, the first and only oral somatostatin alog
Jun 11, 2020: Crinetics Pharmaceuticals confirms completion for half of the enrolled patients in the ongoing phase 2 ACROBAT edge clinical trial for Paltusotine
Apr 06, 2020: Crinetics Pharmaceuticals reports positive interim results for the ACROBAT Edge phase 2 trial of Paltusotine (CRN00808) in acromegaly patients and provides corporate update
Jan 13, 2020: Chiasma announces FDA acceptance of MYCAPSSA New Drug Application Resubmission
Aug 26, 2019: Acromegaly early access program - status update
Jul 23, 2019: Chiasma announces positive phase 3 top-line results from CHIASMA OPTIMAL clinical trial of Mycapssa for the maintence treatment of adults with Acromegaly
Jun 27, 2019: Chiasma provides update on ongoing Mycapssa phase 3 clinical trials
Jun 20, 2019: Camurus Receives IND Acceptance From the FDA to Enter Phase 3 with CAM2029 for Treatment of Acromegaly
Jun 05, 2019: Chiasma strengthens leadership team ahead of anticipated commercial availability of Mycapssa
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Acromegaly, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Targets, H2 2020
Number of Products by Stage and Targets, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020


List of Tables


Number of Products under Development for Acromegaly, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Acromegaly - Pipeline by Antisense Therapeutics Ltd, H2 2020
Acromegaly - Pipeline by Aquestive Therapeutics Inc, H2 2020
Acromegaly - Pipeline by Ascil Proyectos SL, H2 2020
Acromegaly - Pipeline by Auritec Pharmaceuticals Inc, H2 2020
Acromegaly - Pipeline by Camurus AB, H2 2020
Acromegaly - Pipeline by Chiasma Inc, H2 2020
Acromegaly - Pipeline by Crinetics Pharmaceuticals Inc, H2 2020
Acromegaly - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2020
Acromegaly - Pipeline by Dauntless Pharmaceuticals Inc, H2 2020
Acromegaly - Pipeline by DexTech Medical AB, H2 2020
Acromegaly - Pipeline by Enesi Pharma Ltd, H2 2020
Acromegaly - Pipeline by Foresee Pharmaceuticals Co Ltd, H2 2020
Acromegaly - Pipeline by GeneScience Pharmaceuticals Co Ltd, H2 2020
Acromegaly - Pipeline by GlyTech Inc, H2 2020
Acromegaly - Pipeline by Ionis Pharmaceuticals Inc, H2 2020
Acromegaly - Pipeline by Italfarmaco SpA, H2 2020
Acromegaly - Pipeline by OPKO Health Inc, H2 2020
Acromegaly - Pipeline by Pharmathen Global BV, H2 2020
Acromegaly - Pipeline by Strongbridge Biopharma plc, H2 2020
Acromegaly - Dormant Projects, H2 2020
Acromegaly - Discontinued Products, H2 2020